Patents by Inventor Charles Michael Zacharchuk

Charles Michael Zacharchuk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230201155
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: July 22, 2022
    Publication date: June 29, 2023
    Inventors: Laurence Moore, Charles Michael Zacharchuk, Sridhar Krishna Rabindran
  • Publication number: 20220354820
    Abstract: A combination of temsirolimus and trastuzumab in the treatment of cancer is provided. A combination of temsirolimus and HKI-272 is provided. A combination of a trastuzumab and a HKI-272 is also provided. Regimens and kits for treatment of metastatic breast cancer, containing trastuzumab, temsirolimus and/or HKI-272, optionally in combination with other anti-neoplastic agents, or immune modulators are described.
    Type: Application
    Filed: December 10, 2021
    Publication date: November 10, 2022
    Inventors: Laurence Moore, Charles Michael Zacharchuk, Sridhar Krishna Rabindran
  • Publication number: 20220170107
    Abstract: Methods for treating breast cancer, specifically cancers resistant to treatment With one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting tile presence or absence in a patient of one or more of PIK3CA gene amplification a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tifrosine kinase inhibitor.
    Type: Application
    Filed: November 9, 2021
    Publication date: June 2, 2022
    Inventors: Anna Berkenblit, Christina Marie Coughlin, Jay Marshall Feingold, Daniel Stephen Johnston, Andrew Louis Strahs, Charles Michael Zacharchuk
  • Publication number: 20190271047
    Abstract: Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Inventors: Anna Berkenblit, Christina Marie Coughlin, Jay Marshall Feingold, Daniel Stephen Johnston, Andrew Louis Strahs, Charles Michael Zacharchuk
  • Patent number: 10111868
    Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and method for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: October 30, 2018
    Assignee: WYETH LLC
    Inventor: Charles Michael Zacharchuk
  • Publication number: 20170231972
    Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and method for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Application
    Filed: November 2, 2016
    Publication date: August 17, 2017
    Inventor: Charles Michael Zacharchuk
  • Patent number: 9511063
    Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: December 6, 2016
    Assignee: WYETH LLC
    Inventor: Charles Michael Zacharchuk
  • Publication number: 20160222467
    Abstract: Methods for treating breast cancer, specifically cancers resistant to treatment With one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence n a patient o one or inure of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.
    Type: Application
    Filed: April 14, 2016
    Publication date: August 4, 2016
    Inventors: Anna Berkenblit, Christina Marie Coughlin, Jay Marshall Feingold, Daniel Stephen Johnston, Andrew Louis Strahs, Charles Michael Zacharchuk
  • Patent number: 9265784
    Abstract: A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: February 23, 2016
    Assignee: WYETH LLC
    Inventors: Charles Michael Zacharchuk, Susan Elizabeth Quinn, Kenneth Kuan-Yuen Wang, Florence Marie Helene Binlich
  • Publication number: 20140171384
    Abstract: A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Application
    Filed: January 30, 2014
    Publication date: June 19, 2014
    Applicant: WYETH
    Inventors: Charles Michael ZACHARCHUK, Susan Elizabeth QUINN, Kenneth Kuan-Yuen WANG, Florence Marie Helene BINLICH
  • Patent number: 8669273
    Abstract: A combination of a 4-anilino-3-cyanoquinoline compound (e.g. HKI-272, SKI-606, EKB-569) and a capecitabine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: March 11, 2014
    Assignee: Wyeth LLC
    Inventors: Charles Michael Zacharchuk, Susan Elizabeth Quinn, Kenneth Kuan-Yuen Wang, Florence Marie Helene Binlich
  • Publication number: 20130189274
    Abstract: Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.
    Type: Application
    Filed: December 6, 2010
    Publication date: July 25, 2013
    Inventors: Anna Berkenblit, Christina Marie Coughlin, Jay Marshall Feingold, Daniel Stephen Johnston, Andrew Louis Strahs, Charles Michael Zacharchuk
  • Patent number: 8338456
    Abstract: A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: December 25, 2012
    Assignee: Wyeth LLC
    Inventors: Christina Marie Coughlin, Jay Marshall Feingold, Daniel Stephen Johnston, Anna Berkenblit, Andrew Louis Strahs, Charles Michael Zacharchuk
  • Publication number: 20120270896
    Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Application
    Filed: February 24, 2012
    Publication date: October 25, 2012
    Applicant: Wyeth LLC
    Inventor: Charles Michael Zacharchuk
  • Publication number: 20120010240
    Abstract: A cut-point in the quantitative measurement of PTEN protein expression that accurately identifies tumors with two inactivated alleles of the PTEN gene. Patients with a normalized PTEN score of PTEN null will be treated with a pan-ErbB tyrosine kinase inhibitor. A normalized PTEN protein expression score is obtained by comparing the tumor PTEN OD expression value with the non-malignant PTEN OD expression value.
    Type: Application
    Filed: January 4, 2011
    Publication date: January 12, 2012
    Applicant: Wyeth LLC
    Inventors: Christina Marie Coughlin, Jay Marshall Feingold, Daniel Steven Johnston, Anna Berkenblit, Andrew Louis Strahs, Charles Michael Zacharchuk
  • Publication number: 20100069340
    Abstract: This invention is directed to a pharmaceutical composition comprising an Src kinase inhibitor and an aromatase inhibitor, and to the use of a combination of an Src kinase inhibitor and an aromatase inhibitor in treating abnormal cell proliferation and abnormal angiogenesis associated with cancer, including breast cancer.
    Type: Application
    Filed: September 11, 2009
    Publication date: March 18, 2010
    Applicant: Wyeth
    Inventors: Charles Michael Zacharchuk, Frank Charles Boschelli, Jennifer Michele Golas, Kim Timothy Arndt
  • Publication number: 20090312360
    Abstract: A combination of HKI-272 compound and a vinorelbine compound in the treatment of a neoplasm is provided. Regimens, kits, and methods for treatment of neoplasm, including breast cancer including metastatic breast cancer, and lung cancer, using this combination, optionally in combination with other anti-neoplastic agents, or immune modulators are also described.
    Type: Application
    Filed: June 17, 2009
    Publication date: December 17, 2009
    Applicant: Wyeth
    Inventor: Charles Michael Zacharchuk